Psoriasis Treatment Market Size To Hit USD 54.40 Billion By 2032 Driven By Advances In Biologic And Innovative Therapies – SNS Insider

(MENAFN- GlobeNewsWire - Nasdaq) Advancements in biologics, personalized medicine, and rising global prevalence drive the psoriasis treatment market's exponential growth.

Pune, March 12, 2025 (GLOBE NEWSWIRE) -- Psoriasis Treatment Market Overview:

According to SNS Insider, The Psoriasis Treatment Market was worth USD 22.38 billion in 2023, is projected to grow to USD 54.40 billion by 2032 at a compound annual growth rate (CAGR) of 10.4% from 2024 to 2032. The massive growth is largely due to the increasing prevalence of psoriasis globally and huge improvements in biologic treatments with improved efficacy and safety profiles.

Psoriasis, a long-term autoimmune skin disease, impacts millions of people worldwide, causing physical distress and affecting the quality of life. Growing awareness of psoriasis as a significant health issue has driven research and development efforts, leading to new treatment alternatives. Biologic drugs, focusing on specific elements of the immune system, have transformed the treatment of psoriasis, offering patients more effective and specific therapies.

Get a Sample Report of Psoriasis Treatment Market@

Major Players Analysis Listed in this Report are:

• AbbVie Inc. – Humira, Skyrizi
• Amgen Inc. – Enbrel, Otezla
• Johnson & Johnson Services, Inc. – Stelara, Tremfya
• Novartis AG – Cosentyx
• Eli Lilly and Company – Taltz, Olumiant
• AstraZeneca – Saphnelo (under research for psoriasis applications)
• Celgene Corporation (acquired by Bristol-Myers Squibb) – Otezla
• UCB S.A. – Bimzelx
• Merck
• Boehringer Ingelheim International GmbH – Spesolimab (under development for psoriasis)

Psoriasis Treatment Market Report Scope

Report Attributes	Details
Market Size in 2023	US$ 22.38 billion
Market Size by 2032	US$ 54.40 billion
CAGR	CAGR of 10.4% From 2024 to 2032
Base Year	2023
Forecast Period	2024-2032
Historical Data	2020-2022
Key Regional Coverage	North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America)

Segment Analysis

By Drug Class

In 2023, the most significant drug class available in the market for psoriasis treatment was the Tumor Necrosis Factor (TNF) inhibitors, which had a strong market share. The reason behind the success of TNF inhibitors is their proven capability to suppress inflammation and treat symptoms of psoriasis. Interleukin (IL) inhibitors are, however, anticipated to develop at the highest growth rate in the forecast period. IL inhibitors possess a well-defined mode of action, yielding better patient outcomes and less adverse effects, making them an appealing option for psoriasis treatment.

By Route of Administration

The parenteral route dominated the psoriasis treatment market in 2023, reflecting the widespread usage of injectable biologic drugs. Parenteral is often the preferred mode of treatment by both patients and healthcare professionals due to its rapid action and long-lasting efficacy. The topical segment, however, is anticipated to grow at the quickest rate during the forecast period. Topical treatments, including ointments and creams, are used due to their ease of application and minimal systemic absorption, making them best suited for mild to moderate psoriasis.

By Distribution Channel

Hospital pharmacies were the market leaders in 2023, emphasizing their role in providing specialized psoriasis medicines and end-to-end patient services. The convenience of hospital setups and the availability of a wide range of drugs further contribute to their dominance. In comparison, retail pharmacies are expected to hold the highest growth rate during the forecast period. Their convenience and ease of access, coupled with the increased availability of over-the-counter topical treatments, drive their growing significance in the psoriasis treatment market.

Need any customization research on Psoriasis Treatment Market, Enquire Now@

Psoriasis Treatment Market Segmentation

By Drugs Class

• Tumor Necrosis Factor Inhibitors
• Interleukin Inhibitors
• Vitamin D Analogues
• Corticosteriods
• Others

By Route of Administration

• Oral
• Parenteral
• Topical

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

Regional Analysis

North America dominated the global market for the treatment of psoriasis in 2023 with 36.4% share. This can be attributed to the prevalence of psoriasis, highly developed healthcare systems, and the presence of key industry players within the region. The Asia-Pacific region is anticipated to see the maximum growth during the forecast period. Growing awareness of psoriasis, improved healthcare infrastructure, and a huge patient pool are some of the factors contributing to the rapid growth of the market in this region.

Recent Developments

• November 2024: Amgen Inc. gained U.S. FDA approval for biosimilar version of Johnson & Johnson's psoriasis drug, Stelara.
• November 2024: Lords Mark Biotech introduced Tinefcon, a patented drug for the treatment of psoriasis.

Statistical Insights and Trends

• Psoriasis occurs in about 2-3% of the world's population, with differences in prevalence between areas. In North America, 3% of the population is affected, whereas in Asia-Pacific, it is 0.1%-0.5%.
• In North America, biologic treatments accounted for about 60% of psoriasis prescriptions, which indicated a bias towards sophisticated treatments. Topical treatments, on the other hand, were still the most common in the Asia-Pacific region, with about 70% of prescriptions, owing to cost factors and availability.

Buy a Single-User PDF of Psoriasis Treatment Market Analysis & Outlook Report 2024-2032@

Table of Contents – Major Key Points

1. Introduction

2. Executive Summary

3. Research Methodology

4. Market Dynamics Impact Analysis

5. Statistical Insights and Trends Reporting

5.1 Incidence and Prevalence of Psoriasis (2023)

5.2 Severity Distribution and Diagnosis Rates (2023)

5.3 Treatment Adoption Trends (2023), by Region

5.4 Biologic Patent Expiry and Biosimilar Market Entry (2023-2032)

5.5 Patient Preferences and Satisfaction Trends (2023)

5.6 Digital Health and Telemedicine Adoption for Psoriasis Care

6. Competitive Landscape

7. Psoriasis Treatment Market by Drugs Class

8. Psoriasis Treatment Market by Route of Administration

9. Psoriasis Treatment Market by Distribution Channel

10. Regional Analysis

11. Company Profiles

12. Use Cases and Best Practices

13. Conclusion

Access Complete Report Details of Psoriasis Treatment Market Analysis & Outlook 2024-2032@

[For more information or need any customization research mail us at ...]

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

MENAFN12032025004107003653ID1109306709